Tag: Federal Licenses for Cannabis Research

Royal Emerald Pharmaceuticals (REP) Receives Federal Licenses for Cannabis Research

Desert Hot Springs, California, USA (January 18, 2022) – Royal Emerald Pharmaceuticals (REP) is proud to announce that it has received four federal licenses to grow, research, develop, and manufacture alternative drugs derived from cannabis (marijuana) and other botanicals in December 2021. REP is the first-of-its-kind cannabis pharmaceutical company in the United States to receive these highly coveted licenses.